Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#11 / 128 Total
HUGE - FSD Pharma Inc - Stock Price Chart
TickerHUGE [NASD]
CompanyFSD Pharma Inc
CountryCanada
IndustryDrug Manufacturers - Specialty & Generic
Market Cap15.18MEPS (ttm)-0.47
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y31.10%
P/S-EPS next 5Y-
P/B1.12EPS Q/Q73.81%
Dividend-Sales Q/Q-
Insider Own16.97%Inst Own1.21%
Insider Trans0.00%Inst Trans-
Short Float1.11%EarningsNov 15/b
Analyst Recom1.00Target Price5.97
Avg Volume193.25K52W Range0.40 - 1.68
Apr-30-24 08:33AM FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication (ACCESSWIRE) -6.96%
Apr-25-24 07:47AM FSD Pharma Provides Update from Celly Nu's Partnership with Six+One for unbuzzd(TM) (ACCESSWIRE)
Apr-22-24 08:00AM FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM) (ACCESSWIRE)
Apr-17-24 08:00AM FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products (ACCESSWIRE) -7.80%
Apr-15-24 08:00AM FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption (ACCESSWIRE) -12.40%
Apr-07-24 10:55PM FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency (Newsfile)
Apr-01-24 10:00PM FSD Pharma Announces Filing of Year-End 2023 Results (ACCESSWIRE)
Mar-27-24 08:00AM FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults (ACCESSWIRE)
Mar-11-24 08:00AM FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM) (ACCESSWIRE)
Mar-05-24 08:00AM FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum (ACCESSWIRE)
FSD Pharma, Inc. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.
NWGL - Nature Wood Group Ltd ADR - Stock Price Chart
TickerNWGL [NASD]
CompanyNature Wood Group Ltd ADR
CountryChina
IndustryLumber & Wood Production
Market Cap474.10MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own-Inst Own0.00%
Insider Trans-Inst Trans-
Short Float0.04%EarningsFeb 14/b
Analyst Recom-Target Price-
Avg Volume85.60K52W Range3.75 - 21.97
Nature Wood Group Ltd. is a holding company, which engages in forest management, harvesting and down-stream wood processing and distribution of logs, decking, flooring, and sawn timber products. It operates through the Direct Purchase and ODM, and Manufacturing Segments. The Direct Purchase and ODM segment represent sourcing of live wood and owning designed design on wood products for sales to end customers. The Manufacturing segment is involved in manufacturing decking, flooring, or sawn timbers. The company was founded on September 22, 2011 and is headquartered in Macau, China.
NUWE - Nuwellis Inc - Stock Price Chart
TickerNUWE [NASD]
CompanyNuwellis Inc
CountryUSA
IndustryMedical Devices
Market Cap0.90MEPS (ttm)-13.46
P/E-EPS this Y84.64%
Forward P/E-EPS next Y72.32%
PEG-EPS past 5Y84.44%
P/S0.10EPS next 5Y-
P/B0.25EPS Q/Q55.23%
Dividend-Sales Q/Q9.06%
Insider Own0.07%Inst Own3.13%
Insider Trans0.00%Inst Trans1.35%
Short Float12.45%EarningsMay 07/b
Analyst Recom3.00Target Price1.50
Avg Volume1.38M52W Range0.14 - 4.88
Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.
ZAPP - Zapp Electric Vehicles Group Ltd - Stock Price Chart
TickerZAPP [NASD]
CompanyZapp Electric Vehicles Group Ltd
CountryUnited Kingdom
IndustryAuto Manufacturers
Market Cap7.79MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-7.52%
Dividend-Sales Q/Q-
Insider Own55.56%Inst Own4.46%
Insider Trans0.00%Inst Trans-
Short Float0.57%Earnings-
Analyst Recom-Target Price-
Avg Volume54.06K52W Range2.48 - 200.00
Zapp Electric Vehicles Group Ltd. designs, manufactures and sells electric vehicles. It offers maintenance and repair of motorcycles and related parts and accessories. The company was founded by Swin Chatsuwan, Jeremy North, Warin Thanathawee and Kiattipong Arttachariya in 2017 and is headquartered in London, the United Kingdom.
GWAV - Greenwave Technology Solutions Inc - Stock Price Chart
TickerGWAV [NASD]
CompanyGreenwave Technology Solutions Inc
CountryUSA
IndustryWaste Management
Market Cap9.27MEPS (ttm)-2.96
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y39.15%
P/S0.28EPS next 5Y-
P/B-EPS Q/Q62.49%
Dividend-Sales Q/Q50.29%
Insider Own8.07%Inst Own1.72%
Insider Trans0.00%Inst Trans13.46%
Short Float0.62%Earnings-
Analyst Recom1.00Target Price2.45
Avg Volume4.97M52W Range0.06 - 1.12
Greenwave Technology Solutions, Inc. is an emerging growth company, which engages in recycling ferrous metal. It also recycles nonferrous metals including aluminum, copper, stainless steel, nickel, brass, titanium, lead, alloys, and mixed metal products. The company was founded on April 26, 2013 and is headquartered in Chesapeake, VA.
BOLD - Boundless Bio Inc. - Stock Price Chart
TickerBOLD [NASD]
CompanyBoundless Bio Inc.
CountryUSA
IndustryBiotechnology
Market Cap222.40MEPS (ttm)-
P/E-EPS this Y92.13%
Forward P/E-EPS next Y-19.84%
PEG-EPS past 5Y-
P/S-EPS next 5Y13.20%
P/B-EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own46.38%Inst Own12.31%
Insider Trans9.70%Inst Trans-
Short Float4.31%Earnings-
Analyst Recom1.00Target Price23.00
Avg Volume265.47K52W Range9.83 - 15.24
Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company was founded by Vineet Bafna, Paul Mischel, Benjamin F. Cravatt, and Jonathan E. Lim on April 10, 2018 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RA CAPITAL MANAGEMENT, L.P.10% OwnerApr 02 '24Buy16.00312,5005,000,0001,884,787Apr 04 04:15 PM
ARCH Venture Fund IX, L.P.10% OwnerApr 02 '24Buy16.00200,0003,200,0001,181,766Apr 04 04:30 PM
CRANDELL KEITH10% OwnerApr 02 '24Buy16.00200,0003,200,0001,181,766Apr 04 04:30 PM
Burow KristinaDirectorApr 02 '24Buy16.00200,0003,200,0001,181,766Apr 04 04:30 PM
WINT - Windtree Therapeutics Inc - Stock Price Chart
TickerWINT [NASD]
CompanyWindtree Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap2.29MEPS (ttm)-146.17
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y66.05%
P/S-EPS next 5Y-
P/B0.44EPS Q/Q93.15%
Dividend-Sales Q/Q-
Insider Own16.82%Inst Own2.94%
Insider Trans0.00%Inst Trans-
Short Float0.61%EarningsApr 17/b
Analyst Recom3.00Target Price18.00
Avg Volume15.77K52W Range4.78 - 35.10
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. It focuses on the treatment of acute cardiovascular and acute pulmonary diseases. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fraser CraigPresident and CEOSep 27 '23Buy1.022,5002,55057,877Sep 28 07:24 AM
Fraser CraigPresident and CEOSep 26 '23Buy0.902,5002,25055,377Sep 27 07:34 AM
ALLR - Allarity Therapeutics Inc - Stock Price Chart
TickerALLR [NASD]
CompanyAllarity Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap0.64MEPS (ttm)-4117.54
P/E-EPS this Y86.06%
Forward P/E-EPS next Y-6.29%
PEG-EPS past 5Y57.56%
P/S-EPS next 5Y-
P/B-EPS Q/Q99.91%
Dividend-Sales Q/Q-
Insider Own10.59%Inst Own0.62%
Insider Trans0.00%Inst Trans-
Short Float25.01%EarningsMar 08/b
Analyst Recom1.00Target Price8.00
Avg Volume530.04K52W Range1.26 - 372.00
Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company operates in two geographic areas: Denmark and the United States. The company was founded on April 4, 2021 and is headquartered in Boston, MA.
NRXP - NRX Pharmaceuticals Inc - Stock Price Chart
TickerNRXP [NASD]
CompanyNRX Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap20.86MEPS (ttm)-1.54
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-235.69%
Dividend-Sales Q/Q-
Insider Own20.20%Inst Own4.20%
Insider Trans0.00%Inst Trans-
Short Float6.69%EarningsMar 28/b
Analyst Recom1.00Target Price20.00
Avg Volume234.19K52W Range2.21 - 12.00
Apr-30-24 08:30AM NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression (PR Newswire) -27.32%
Apr-18-24 08:56AM Why Is NRX Pharmaceuticals (NRXP) Stock Down 29% Today? (InvestorPlace) -27.75%
08:32AM NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement (PR Newswire)
08:30AM NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock (PR Newswire)
Apr-17-24 04:45PM NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock (PR Newswire)
08:30AM NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections (PR Newswire)
Apr-15-24 08:30AM NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine) (PR Newswire)
Apr-08-24 08:30AM NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression (PR Newswire)
Apr-04-24 12:00PM NRx Pharmaceuticals (NRXP) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +9.70%
Apr-02-24 10:33AM NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q4 2023 Earnings Call Transcript (Insider Monkey)
NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hurvitz ChaimDirectorAug 30 '23Buy0.2970,00020,125570,000Sep 11 09:15 AM
Gorovitz AaronDirectorAug 30 '23Buy0.3235,00011,196105,000Sep 11 09:19 AM
Javitt Jonathan CChief ScientistAug 23 '23Buy0.33100,00033,000446,332Aug 24 12:14 PM
Javitt Jonathan CChief ScientistAug 22 '23Buy0.32200,00064,400346,332Aug 23 09:24 AM
OI - O-I Glass Inc - Stock Price Chart
TickerOI [NYSE, RUT]
CompanyO-I Glass Inc
CountryUSA
IndustryPackaging & Containers
Market Cap1.93BEPS (ttm)-1.59
P/E-EPS this Y-32.76%
Forward P/E5.07EPS next Y19.53%
PEG-EPS past 5Y-
P/S0.28EPS next 5Y-1.40%
P/B1.21EPS Q/Q-65.25%
Dividend-Sales Q/Q-13.00%
Insider Own1.51%Inst Own99.20%
Insider Trans0.00%Inst Trans0.14%
Short Float3.01%EarningsApr 30/a
Analyst Recom1.91Target Price19.56
Avg Volume1.76M52W Range13.56 - 23.57
O-I Glass, Inc. engages in the manufacturing of glass products. It offers products to the food and beverage sectors. It operates through the Americas and Europe geographical segments. The company was founded in 1929 and is headquartered in Perrysburg, OH.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lopez Andres AlbertoPresident & CEOJun 07 '23Sale22.5476,1321,715,7561,036,969Jun 08 04:18 PM
Lopez Andres AlbertoPresident & CEOJun 06 '23Sale22.0259,1741,303,1301,113,101Jun 08 04:18 PM
12345671013